ArticleJournal of clinical pathology2026
TCRbeta1/TCRbeta2 (TRBC1/TRBC2) antibody pair for determining T-cell monotypia as a surrogate for clonality in formalin-fixed paraffin-embedded material.
Article in Journal of clinical pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TRBC1/TRBC2 RNA In Situ Hybridization as a Diagnostic Approach for Canine and Feline T-Cell Lymphoma: A Proof-of-Concept Study.Veterinary sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimT-cell lymphomas are often histologically indistinguishable from benign T-cell infiltrates. Clonality testing is frequently required for diagnosis. It lacks the spatial context and is slow and expensive, relying on complex multiplexed PCR reactions, interpreted by scientists or pathologists with specialist molecular training. We set out to make monoclonal antibodies to develop a novel immunohistochemical test for T-cell lymphoma, analogous to the kappa/lambda assay for B-cell and plasma cell neoplasms.
methodsWe developed a pair of highly specific monoclonal antibodies against the two alternatively used but very similar T-cell receptor β constant regions, TCRβ1 and TCRβ2 (encoded by the TRBC1 and TRBC2 gene segments). We demonstrate the feasibility of immunohistochemical detection of TCRβ1 and TCRβ2 in formalin-fixed, paraffin-embedded tissue as a novel diagnostic strategy for T-cell lymphomas.
resultsSingle immunostaining results are presented for 13 T-cell lymphomas and 8 benign T-cell populations, together with illustrative examples of TCRβ1/2 double immunostaining. Finally, we show that this single immunostaining is amenable to automated cell counting, permitting accurate calculation of the TCRβ2:TCRβ1 ratio.
conclusionThis novel assay can be used in a similar way to the kappa/lambda assay for B-cell and plasma cell neoplasms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.